HPV18 E6

Accession: H001505

Uniprot: A9XFE2

Protein: E6

Organism: Human papillomavirus type 18

Function

It is an oncogenic protein which causes transformation of host cell by binding to p53 tumour suppressor protein. For binding, it requires E6-associated protein (E6-AP) which is involved in the ubiquitin ligase pathway. E6-AP binds ubiquitin to the p53 pro

Sequence&Mutation

         .         .         .         .         .         .
MARFEDPTRR YKLPDLCTE NTSLQDIEI CVYCKTVLE TGVFEFAFK LFVVYRDSI
         .         .         .         .         .         .
PHAACHKCID YSRIRELRH SDSVYGDTL KLTNTGLYN LIRCLRCQK LNPAEKLRH
         .         .         .                              
LNEKRRFHNI GHYRGQCHS CNRARQERL RRRETQV  

Epitope&Mutation

>H001505_E6
MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTGVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV
············KLPDLCTEL(A*0201)·································································································································
·······················SLQDIEITCV(A*0201)·····················································································································
························LQDIEITCV(A*0201)·····················································································································
··························DIEITCVYCKTVLEL(DR)·················································································································
··············································FAFKDLFVV(A*0201)·······························································································
················································FKDLFVVYRDSIPHA(DR)···························································································
··················································DLFVVYRDSIPHAACHKCIDFY(DQ*0301)·············································································
···················································LFVVYRDSIPHAACH(DR*03 and DR*16)···········································································
···················································LFVVYRDSIP(DRB1*03)························································································
···················································LFVVYRDSIP(DRB1*16)························································································
··································································KCIDFYSRI(A*0201)···········································································
······································································FYSRIRELRHYSDSVYGDTLEK(DQ*0501)·························································
···························································································KLTNTGLYNL(A*0201)·················································
································································································GLYNLLIRCLRCQKP(DR*08 and DR*16)······························
···································································································NLLIRCLRC(A*0201)··········································
········································································································CLRCQKPLNPAEKLR(DR)···································